MASLD、糖尿病与PMOS在女性不同生命阶段的交互作用
该叙述性综述汇总了代谢功能障碍相关脂肪性肝病(MASLD)、2型糖尿病与多内分泌代谢性卵巢综合征(PMOS,旧称PCOS)在女性中的流行病学与机制关联。MASLD影响全球约38%成人,2型糖尿病约10.5%,PMOS影响10-13%育龄女性。雄激素通过上调肝脏脂质生成基因、激活肝星状细胞及抑制性激素结合球蛋白促进肝纤维化,青春期、妊娠和绝经期是易感窗口。
要点
- MASLD、2型糖尿病与PMOS共享脂肪组织功能障碍、脂联素异常及线粒体损伤机制。
- 雄激素直接上调肝脏脂质生成基因并激活肝星状细胞,促进纤维化。
- 青春期、妊娠和绝经期是女性代谢与肝脏疾病易感的关键窗口。
核心结论
- MASLD、2型糖尿病与PMOS在女性中通过共享代谢与激素机制相互交织,需按生命阶段制定筛查与早期干预策略。
研究设计与样本
- 叙述性综述,汇总现有流行病学与机制研究证据,未报告系统检索范围或样本量。
主要发现
- MASLD影响全球约38%成人,2型糖尿病约10.5%,PMOS影响10-13%育龄女性。
- 雄激素通过上调肝脏脂质生成基因、激活肝星状细胞及抑制性激素结合球蛋白促进肝纤维化。
- MASLD与2型糖尿病及PMOS共享脂肪组织功能障碍、脂肪因子失调、肝脏脂质调节异常和线粒体损伤机制。
- 青春期、妊娠和绝经期激素变化调节上述共享机制,构成易感窗口。
临床怎么用
- 对PMOS女性应关注MASLD与2型糖尿病风险,结合青春期、妊娠和绝经期进行阶段特异性筛查。
- 针对共享机制(胰岛素抵抗、雄激素过多、慢性炎症)早期干预,以减少长期心血管代谢与肝脏疾病负担。
局限性
- 为叙述性综述,未报告系统检索策略、纳入标准或偏倚评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes, which affect approximately 38% and 10.5%, respectively, of adults globally, intersect critically in women through polyendocrine metabolic ovarian syndrome (PMOS), previously known as polycystic ovary syndrome (PCOS), a prevalent but under-recognised cardiometabolic disorder affecting 10-13% of reproductive-age women. Beyond its reproductive consequences, PMOS promotes hepatic disease through hyperandrogenism, insulin resistance and chronic inflammation. Androgens directly upregulate hepatic lipogenic gene expression, activate hepatic stellate cells via androgen receptor signalling, and suppress sex hormone-binding globulin, creating a pro-fibrotic, lipotoxic hepatic environment. MASLD shares pathophysiological mechanisms with type 2 diabetes and PMOS, including adipose tissue dysfunction, adipokine dysregulation, hepatic lipid dysregulation and mitochondrial impairment. These shared mechanisms are further modulated by hormonal transitions during adolescence, pregnancy and menopause, with each representing a critical window of vulnerability. This narrative review consolidates current epidemiological and mechanistic insights linking MASLD, type 2 diabetes and PMOS in women, highlights the relevance of experimental models for elucidating shared disease pathways, and informs life stage-tailored screening and early intervention strategies to reduce long-term cardiometabolic and liver-related morbidity in affected women.
引用
- Stener-Victorin E, Carlsson S, Hagström H, et al. MASLD, diabetes and PMOS across the female life stages. Diabetologia. 2026. PMID: 42249186. doi:10.1007/s00125-026-06761-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。